144 related articles for article (PubMed ID: 12750260)
1. Metabolic activation of temozolomide measured in vivo using positron emission tomography.
Saleem A; Brown GD; Brady F; Aboagye EO; Osman S; Luthra SK; Ranicar AS; Brock CS; Stevens MF; Newlands E; Jones T; Price P
Cancer Res; 2003 May; 63(10):2409-15. PubMed ID: 12750260
[TBL] [Abstract][Full Text] [Related]
2. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Rosso L; Brock CS; Gallo JM; Saleem A; Price PM; Turkheimer FE; Aboagye EO
Cancer Res; 2009 Jan; 69(1):120-7. PubMed ID: 19117994
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
Riccardi A; Mazzarella G; Cefalo G; Garrè ML; Massimino M; Barone C; Sandri A; Ridola V; Ruggiero A; Mastrangelo S; Lazzareschi I; Caldarelli M; Maira G; Madon E; Riccardi R
Cancer Chemother Pharmacol; 2003 Dec; 52(6):459-64. PubMed ID: 13680160
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
Meikle SR; Matthews JC; Brock CS; Wells P; Harte RJ; Cunningham VJ; Jones T; Price P
Cancer Chemother Pharmacol; 1998; 42(3):183-93. PubMed ID: 9685053
[TBL] [Abstract][Full Text] [Related]
6. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
Ostermann S; Csajka C; Buclin T; Leyvraz S; Lejeune F; Decosterd LA; Stupp R
Clin Cancer Res; 2004 Jun; 10(11):3728-36. PubMed ID: 15173079
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
Panetta JC; Kirstein MN; Gajjar A; Nair G; Fouladi M; Heideman RL; Wilkinson M; Stewart CF
Cancer Chemother Pharmacol; 2003 Dec; 52(6):435-41. PubMed ID: 13680158
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide analogs with improved brain/plasma ratios - Exploring the possibility of enhancing the therapeutic index of temozolomide.
Rai R; Banerjee M; Wong DH; McCullagh E; Gupta A; Tripathi S; Riquelme E; Jangir R; Yadav S; Raja M; Melkani P; Dixit V; Patil U; Shrivastava R; Middya S; Olivares F; Guerrero J; Surya A; Pham SM; Bernales S; Protter AA; Hung DT; Chakravarty S
Bioorg Med Chem Lett; 2016 Oct; 26(20):5103-5109. PubMed ID: 27614414
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Aoki T; Nishikawa R; Mizutani T; Nojima K; Mishima K; Adachi J; Matsutani M
Int J Clin Oncol; 2007 Oct; 12(5):341-9. PubMed ID: 17929115
[TBL] [Abstract][Full Text] [Related]
10. Antitumor imidazotetrazines. 40. Radiosyntheses of [4-11C-carbonyl]- and [3-N-11C-methyl]-8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) for positron emission tomography (PET) studies.
Brown GD; Luthra SK; Brock CS; Stevens MF; Price PM; Brady F
J Med Chem; 2002 Dec; 45(25):5448-57. PubMed ID: 12459013
[TBL] [Abstract][Full Text] [Related]
11. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Charnley N; West CM; Barnett CM; Brock C; Bydder GM; Glaser M; Newlands ES; Swindell R; Matthews J; Price P
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):331-8. PubMed ID: 16839701
[TBL] [Abstract][Full Text] [Related]
12. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
13. The effect of an adenosine A
Jackson S; Weingart J; Nduom EK; Harfi TT; George RT; McAreavey D; Ye X; Anders NM; Peer C; Figg WD; Gilbert M; Rudek MA; Grossman SA
Fluids Barriers CNS; 2018 Jan; 15(1):2. PubMed ID: 29332604
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
[TBL] [Abstract][Full Text] [Related]
15. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Devineni D; Klein-Szanto A; Gallo JM
Cancer Res; 1996 May; 56(9):1983-7. PubMed ID: 8616836
[TBL] [Abstract][Full Text] [Related]
16. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Baker SD; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius SE; Dugan M; Cutler D; Batra V; Grochow LB; Donehower RC; Rowinsky EK
Clin Cancer Res; 1999 Feb; 5(2):309-17. PubMed ID: 10037179
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
Reid JM; Stevens DC; Rubin J; Ames MM
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2393-8. PubMed ID: 9815639
[TBL] [Abstract][Full Text] [Related]
18. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
Brock CS; Young H; O'Reilly SM; Matthews J; Osman S; Evans H; Newlands ES; Price PM
Br J Cancer; 2000 Feb; 82(3):608-15. PubMed ID: 10682673
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide and treatment of malignant glioma.
Friedman HS; Kerby T; Calvert H
Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
[TBL] [Abstract][Full Text] [Related]
20. Disposition and pharmacokinetics of temozolomide in rat.
Reyderman L; Statkevich P; Thonoor CM; Patrick J; Batra VK; Wirth M
Xenobiotica; 2004 May; 34(5):487-500. PubMed ID: 15370964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
